Annals of the American Thoracic Society最新文献

{"title":"Impact on Pulmonary Hypertension Hemodynamic Classification Based on the Methodology Used to Measure Pulmonary Artery Wedge Pressure and Cardiac Output.","authors":"Sandeep Sahay, James Lane, Megan G Sharpe, David Toth, Deborah Paul, Matthew T Siuba, Adriano R Tonelli","doi":"10.1513/AnnalsATS.202303-216OC","DOIUrl":"10.1513/AnnalsATS.202303-216OC","url":null,"abstract":"<p><p><b>Rationale:</b> Guidelines recommend using end-expiration pulmonary pressure measurements to determine the hemodynamic subgroups in pulmonary hypertension. Pulmonary artery wedge pressure (PAWP) determinations averaged across the respiratory cycle (PAWPav) instead of PAWP at end-expiration (PAWPee) and cardiac output (CO) measured by Fick (CO_Fick) instead of thermodilution (CO_TD) may affect the hemodynamic classification of pulmonary hypertension. <b>Objectives:</b> To assess the impact on the pulmonary hypertension hemodynamic classification of the use of PAWPee versus PAWPav as well as CO_Fick versus CO_TD. <b>Methods:</b> This was a single-center retrospective study of consecutive patients (<i>n</i> = 151) who underwent right heart catheterization with CO_TD, CO_Fick, PAWPee, and PAWPav. A secondary cohort consisted of consecutive patients (<i>n</i> = 71) who had mean pulmonary artery pressure at end-expiration (mPAPee) and mPAP averaged across the respiratory cycle (mPAPav) measured, as well as PAWPee and PAWPav. <b>Results:</b> The PAWPee and PAWPav were 16.8 ± 6.4 and 15.1 ± 6.8 mm Hg, respectively, with a mean difference of 1.7 ± 2.1 mm Hg. The CO_TD and CO_Fick determinations were 5.0 ± 2.4 and 5.3 ± 2.5 L/min, respectively, with a mean difference of -0.4 ± 1.3 L/min. The hemodynamic group distribution was significantly different when using PAWPee versus PAWPav, when using either CO_TD or CO_Fick (<i>P</i> < 0.001 for both comparisons), and these results were consistent in our secondary cohort. The pulmonary hypertension hemodynamic group distribution was not significantly different between CO_TD and CO_Fick when using either PAWPee or PAWPav. <b>Conclusions:</b> The methodology used to measure PAWP, either at end-expiration or averaged across the respiratory cycle, significantly impacts the hemodynamic classification of pulmonary hypertension.</p>","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1752-1759"},"PeriodicalIF":8.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9969816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease.","authors":"Ferhan Saleem, Christopher J Ryerson, Nandini Sarma, Kerri Johannson, Veronica Marcoux, Jolene Fisher, Deborah Assayag, Helene Manganas, Nasreen Khalil, Julie Morisset, Ian N Glaspole, Nicole Goh, Justin M Oldham, Gerard Cox, Charlene Fell, Andrea S Gershon, Andrew Halayko, Nathan Hambly, Stacey D Lok, Shane Shapera, Teresa To, Pearce G Wilcox, Alyson W Wong, Martin Kolb, Yet H Khor","doi":"10.1513/AnnalsATS.202303-208OC","DOIUrl":"10.1513/AnnalsATS.202303-208OC","url":null,"abstract":"<p><p><b>Rationale:</b> Hypoxemia in fibrotic interstitial lung disease (ILD) indicates disease progression and is of prognostic significance. The onset of hypoxemia signifies disease progression and predicts mortality in fibrotic ILD. Accurately predicting new-onset exertional and resting hypoxemia prompts appropriate patient discussion and timely consideration of home oxygen. <b>Objectives:</b> We derived and externally validated a risk prediction tool for both new-onset exertional and new-onset resting hypoxemia. <b>Methods:</b> This study used ILD registries from Canada for the derivation cohort and from Australia and the United States for the validation cohort. New-onset exertional and resting hypoxemia were defined as nadir oxyhemoglobin saturation < 88% during 6-minute-walk tests, resting oxyhemoglobin saturation < 88%, or the initiation of ambulatory or continuous oxygen. Candidate predictors included patient demographics, ILD subtypes, and pulmonary function. Time-varying Cox regression was used to identify the top-performing prediction model according to Akaike information criterion and clinical usability. Model performance was assessed using Harrell's C-index and goodness-of-fit (GoF) likelihood ratio test. A categorized risk prediction tool was developed. <b>Results:</b> The best-performing prediction model for both new-onset exertional and new-onset resting hypoxemia included age, body mass index, a diagnosis of idiopathic pulmonary fibrosis, and percent predicted forced vital capacity and diffusing capacity of carbon monoxide. The risk prediction tool exhibited good performance for exertional hypoxemia (C-index, 0.70; GoF, <i>P</i> = 0.85) and resting hypoxemia (C-index, 0.77; GoF, <i>P</i> = 0.27) in the derivation cohort, with similar performance in the validation cohort except calibration for resting hypoxemia (GoF, <i>P</i> = 0.001). <b>Conclusions:</b> This clinically applicable risk prediction tool predicted new-onset exertional and resting hypoxemia at 6 months in the derivation cohort and a diverse validation cohort. Suboptimal GoF in the validation cohort likely reflected overestimation of hypoxemia risk and indicated that the model is not flawed because of underestimation of hypoxemia.</p>","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1726-1734"},"PeriodicalIF":8.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10237306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Biologic Therapy on Total Body Composition in Severe Asthma.","authors":"Edith Visser, Lianne Ten Have, Anneke Ten Brinke, Kim de Jong","doi":"10.1513/AnnalsATS.202304-321RL","DOIUrl":"10.1513/AnnalsATS.202304-321RL","url":null,"abstract":"","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1825-1828"},"PeriodicalIF":8.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10234345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Far-UVC: Technology Update with an Untapped Potential to Mitigate Airborne Infections.","authors":"P Jacob Bueno de Mesquita, Rosemary K Sokas, Mary B Rice, Edward A Nardell","doi":"10.1513/AnnalsATS.202305-460VP","DOIUrl":"10.1513/AnnalsATS.202305-460VP","url":null,"abstract":"","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1700-1702"},"PeriodicalIF":6.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10704226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10515653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis.","authors":"John S Kim, Sydney B Montesi, Ayodeji Adegunsoye, Stephen M Humphries, Margaret L Salisbury, Lida P Hariri, Jonathan A Kropski, Luca Richeldi, Athol U Wells, Simon Walsh, R Gisli Jenkins, Ivan Rosas, Imre Noth, Gary M Hunninghake, Fernando J Martinez, Anna J Podolanczuk","doi":"10.1513/AnnalsATS.202303-188PS","DOIUrl":"10.1513/AnnalsATS.202303-188PS","url":null,"abstract":"","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1683-1693"},"PeriodicalIF":6.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10704236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Hybrid Effectiveness/Implementation Clinical Trial of Adherence to Long-Term Oxygen Therapy for Chronic Obstructive Pulmonary Disease.","authors":"Valentin Prieto-Centurion, Kristen E Holm, Richard Casaburi, Janos Porszasz, Sanjib Basu, Nina E Bracken, Richard Gallardo, Vanessa Gonzalez, Sai D Illendula, Robert A Sandhaus, Jamie L Sullivan, Linda J Walsh, Lynn B Gerald, Jerry A Krishnan","doi":"10.1513/AnnalsATS.202302-104OC","DOIUrl":"10.1513/AnnalsATS.202302-104OC","url":null,"abstract":"<p><p><b>Rationale:</b> Interventions to promote adherence to long-term oxygen therapy (LTOT) in chronic obstructive pulmonary disease (COPD) are needed. <b>Objectives:</b> To examine the real-world effectiveness of phone-based peer coaching on LTOT adherence and other outcomes in a pragmatic trial of patients with COPD. <b>Methods:</b> In a hybrid effectiveness/implementation pragmatic trial, patients were randomized to receive phone-based proactive coaching (educational materials, five phone-based peer coaching sessions over 60 d), reactive coaching (educational materials, peer coaching when requested), or usual care. Study staff members collected baseline and outcome data via phone at 30, 60, and 90 days after randomization. Adherence to LTOT over 60 days, the primary effectiveness outcome, was defined as mean LTOT use ⩾17.7 h/d. LTOT use was calculated using information about home oxygen equipment use in worksheets completed by study participants. Comparisons of adherence to LTOT between each coaching group and the usual care group using multivariable logistic regression models were prespecified as the primary analyses. Secondary effectiveness outcomes included Patient Reported Outcome Management Information System measures for physical, emotional, and social health. We assessed early implementation domains in the reach, adoption, and implementation framework. <b>Results:</b> In 444 participants, the proportions who were adherent to LTOT at 60 days were 74% in usual care, 84% in reactive coaching, and 70% in proactive coaching groups. Although reach, adoption by stakeholder partners, and intervention fidelity were acceptable, complete LTOT adherence data were available in only 73% of participants. Reactive coaching (adjusted odds ratio, 1.77; 97.5% confidence interval, 0.80-3.90) and proactive coaching (adjusted odds ratio, 0.70; 97.5% confidence interval, 0.34-1.46) did not improve adherence to LTOT compared with usual care. However, proactive coaching significantly reduced depressive symptoms and sleep disturbance compared with usual care and reduced depressive symptoms compared with reactive coaching. Unexpectedly, LTOT adherence was significantly lower in the proactive compared with the reactive coaching group. <b>Conclusions:</b> The results were inconclusive about whether a phone-based peer coaching strategy changed LTOT adherence compared with usual care. Further studies are needed to confirm the potential benefits of proactive peer coaching on secondary effectiveness outcomes and differences in LTOT adherence between proactive and reactive peer coaching. Clinical trial registered with ClinicalTrials.gov (NCT02098369).</p>","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1561-1570"},"PeriodicalIF":6.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10188303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elexacaftor/Tezacaftor/Ivacaftor Improves Bronchial Artery Dilatation Detected by Magnetic Resonance Imaging in Patients with Cystic Fibrosis.","authors":"Lena Wucherpfennig,&nbsp;Simon M F Triphan,&nbsp;Sabine Wege,&nbsp;Hans-Ulrich Kauczor,&nbsp;Claus P Heussel,&nbsp;Olaf Sommerburg,&nbsp;Mirjam Stahl,&nbsp;Marcus A Mall,&nbsp;Monika Eichinger,&nbsp;Mark O Wielpütz","doi":"10.1513/AnnalsATS.202302-168OC","DOIUrl":"10.1513/AnnalsATS.202302-168OC","url":null,"abstract":"<p><p><b>Rationale:</b> Magnetic resonance imaging (MRI) detects improvements in mucus plugging and bronchial wall thickening, but not in lung perfusion in patients with cystic fibrosis (CF) treated with elexacaftor/tezacaftor/ivacaftor (ETI). <b>Objectives:</b> To determine whether bronchial artery dilatation (BAD), a key feature of advanced lung disease, indicates irreversibility of perfusion abnormalities and whether BAD could be reversed in CF patients treated with ETI. <b>Methods:</b> A total of 59 adults with CF underwent longitudinal chest MRI, including magnetic resonance angiography twice, comprising 35 patients with CF (mean age, 31 ± 7 yr) before (MRI1) and after (MRI2) at least 1 month (mean duration, 8 ± 4 mo) on ETI therapy and 24 control patients with CF (mean age, 31 ± 7 yr) without ETI. MRI was assessed using the validated chest MRI score, and the presence and total lumen area of BAD were assessed with commercial software. <b>Results:</b> The MRI global score was stable in the control group from MRI1 to MRI2 (mean difference, 1.1 [-0.3, 2.4]; <i>P</i> = 0.054), but it was reduced in the ETI group (-10.1 [-0.3, 2.4]; <i>P</i> < 0.001). In the control and ETI groups, BAD was present in almost all patients at baseline (95% and 94%, respectively), which did not change at MRI2. The BAD total lumen area did not change in the control group from MRI1 to MRI2 (1.0 mm² [-0.2, 2.2]; <i>P</i> = 0.099) but decreased in the ETI group (-7.0 mm² [-8.9, -5.0]; <i>P</i> < 0.001). This decrease correlated with improvements in the MRI global score (<i>r</i> = 0.540; <i>P</i> < 0.001). <b>Conclusions:</b> Our data show that BAD may be partially reversible under ETI therapy in adult patients with CF who have established disease.</p>","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1595-1604"},"PeriodicalIF":8.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9997305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative Loss of Small Pulmonary Vessels on Imaging and Risk of Recurrence of Resected Lung Adenocarcinoma.","authors":"Andrew J Synn, Tess D Litchman, Constance De Margerie-Mellon, Alexander A Bankier, Farbod N Rahaghi, George R Washko, Raúl San José Estépar, Paul A VanderLaan, Mary B Rice","doi":"10.1513/AnnalsATS.202303-191RL","DOIUrl":"10.1513/AnnalsATS.202303-191RL","url":null,"abstract":"","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1673-1676"},"PeriodicalIF":6.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10374236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep Testing and Mortality in a Propensity-matched Cohort of Patients with Chronic Obstructive Pulmonary Disease.","authors":"Lucas M Donovan,&nbsp;Travis Wai,&nbsp;Laura J Spece,&nbsp;Kevin I Duan,&nbsp;Matthew F Griffith,&nbsp;Aristotle Leonhard,&nbsp;Robert Plumley,&nbsp;Sophia A Hayes,&nbsp;Fernando Picazo,&nbsp;Kristina Crothers,&nbsp;Vishesh K Kapur,&nbsp;Brian N Palen,&nbsp;David H Au,&nbsp;Laura C Feemster","doi":"10.1513/AnnalsATS.202303-275OC","DOIUrl":"10.1513/AnnalsATS.202303-275OC","url":null,"abstract":"<p><p><b>Rationale:</b> Many advocate the application of propensity-matching methods to real-world data to answer key questions around obstructive sleep apnea (OSA) management. One such question is whether identifying undiagnosed OSA impacts mortality in high-risk populations, such as those with chronic obstructive pulmonary disease (COPD). <b>Objectives:</b> Assess the association of sleep testing with mortality among patients with COPD and a high likelihood of undiagnosed OSA. <b>Methods:</b> We identified patients with COPD and a high likelihood of undiagnosed OSA. We then distinguished those receiving sleep testing within 90 days of index COPD encounters. We calculated propensity scores for testing based on 37 variables and compared long-term mortality in matched groups. In sensitivity analyses, we compared mortality using inverse propensity weighting and instrumental variable methods. We also compared the incidence of nonfatal events including adverse outcomes (hospitalizations and COPD exacerbations) and routine services that are regularly indicated in COPD (influenza vaccination and pulmonary function testing). We compared the incidence of each nonfatal event as a composite outcome with death and separately compared the marginal probability of each nonfatal event independently, with death as a competing risk. <b>Results:</b> Among 135,958 patients, 1,957 (1.4%) received sleep testing. We propensity matched all patients with sleep testing to an equal number without testing, achieving excellent balance on observed confounders, with standardized differences < 0.10. We observed lower mortality risk among patients with sleep testing (incidence rate ratio, 0.88; 95% confidence interval [CI], 0.79-0.99) and similar results using inverse propensity weighting and instrumental variable methods. Contrary to mortality, we found that sleep testing was associated with a similar or greater risk for nonfatal adverse events, including inpatient COPD exacerbations (subhazard ratio, 1.29; 95% CI, 1.02-1.62) and routine services like influenza vaccination (subhazard ratio, 1.26; 95% CI, 1.17-1.36). <b>Conclusions:</b> Our disparate findings can be interpreted in multiple ways. Sleep testing may indeed cause both reduced mortality and greater incidence of nonfatal adverse outcomes and routine services. However, it is also possible that our findings stem from residual confounding by patients' likelihood of accessing care. Given the limitations of propensity-based analyses, we cannot confidently distinguish these two possibilities. This uncertainty highlights the limitations of using propensity-based analyses to guide patient care and policy decisions.</p>","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1642-1653"},"PeriodicalIF":8.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10054370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Histamine Metabolites with Disease Severity and Mortality in Pulmonary Arterial Hypertension.","authors":"Brandon S Peplinski, Jonathan Buber, Sina A Gharib, Hongyang Pi, Daniel Raftery, Peter J Leary","doi":"10.1513/AnnalsATS.202304-302RL","DOIUrl":"10.1513/AnnalsATS.202304-302RL","url":null,"abstract":"","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1676-1679"},"PeriodicalIF":6.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10152527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}